I should note that the same server problem with the first link occurs in Firefox 3.5.11 as well. When I log in I get a similar error that says the page is not redirecting properly. "Firefox has detected that the server is redirecting the request for this address in a way that will never complete."
Carbon Tet
Musings of an organic chemist
Wednesday, August 25, 2010
CS Support Forum - Safari Problem
I should note that the same server problem with the first link occurs in Firefox 3.5.11 as well. When I log in I get a similar error that says the page is not redirecting properly. "Firefox has detected that the server is redirecting the request for this address in a way that will never complete."
Monday, August 23, 2010
ACS Blogging - Cambridgesoft
Update: After lunch I returned to the expo and happened to bump into some of the McGraw Hill folks at the CambridgeSoft booth. They were showing their upcoming educational tools combining Connect with a ChemDraw plugin and Blackboard interface. This product looks very promising. Anyway, I got pulled back into some lengthy conversations. I do want to set the record straight. My rant above is all about CambridgeSoft's Mac support. Their windows products are actually quite good and improving all the time. Although I stand behind my statement that this company is a follower and not an innovator, I understand the economics of business. It is our job to let the company know that the market demand is out there. So, if all you pharmaceutical companies would just switch over to Macs and ask CambridgeSoft to start delivering their software to you, I would really appreciate it. And CambridgeSoft, I want to say please don't underestimate the growing Mac market. Frankly if you would just focus on making ChemDraw work well we would be ecstatic. And if you could make a simple Chem drawing app for the iPad that would be the icing on the cake!
Sunday, August 22, 2010
ACS Liveblogging Sunday Morning
11:15 am Jacobson is talking up reaction calorimetry for kinetic analysis. Not really new but I suppose organic chemists haven't utilized this great technique.
11:26 am Some nice new insight into the Co-salen catalyzed epoxide hydrolysis being presented. It seems using a tosylate counter ion on the cobalt is very different from Cl or OAc. The rate doesn't seem to slow down but expoxide opening is very reversible due to the good leaving group ability of tosylate. This leads to racemization and poor kinetic resolution.
11:40 am Jacobson appears to be flustered today. He's stumbling over words and seems unsure of his slides. Never the less he still has great science to share. It appears that chirality on both the activated epoxide electrophile and the Co-OH nucleophile are important for kinetic resolution. Enantioselectivity is not dependent on the chiral backbone as the ligand complex forms the same stepped configuration of the arylation groups of the salen regardless of the backbone. It is only necessary that backbone allows them to have the same sense of chirality.
11:50 am Ooh. Cyclic oligomers of the salen ligand with local C2 symmetry. Very efficient HKR at only 0.001 mol% loading. Salens connected with ether linkages. Rate is much improved over the monomeric catalyst.
Saturday, August 21, 2010
Boston or Bust
Sunday, August 1, 2010
Carbon Tetrachloride
The Demise of the Chemistry Blog
Atom Pushers Anonymous
Monday, December 29, 2008
Criminal Chemists
Thursday, October 9, 2008
NIH to cut
They claim this will result in funding "high quality" applications earlier with fewer resubmissions. I don't know that this is the case. I worry about less proposals being funded.
"This policy applies to all applications, including applications submitted under the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, Career Development Awards, Individual Fellowships, Institutional Training Grants, Resource Grants, Program Projects, and Centers. Currently no amendments are permitted for applications received in response to a Request for Applications (RFA) unless it is specified in the Funding Opportunity Announcement, in which case only one amendment will be permitted."
Wednesday, October 8, 2008
For the Science Geeks
Wednesday, September 24, 2008
Zerhouni Steps Down
Dear Friends and Colleagues in the extramural community,I'm not quite sure how I feel about this. I don't know that he did a fantastic job. He had some controversial moments. And I think he was largely behind the fiasco known as grants.gov ($2 billion spent on grants.gov and you can't buy a computer today that you can submit a grant with - no Mac OS, no Windows Vista).
Today, I informed my NIH colleagues, including staff, scientists, administrators, contractors, and trainees that at the end of October, I will be leaving my position as NIH Director to explore new opportunities and to devote much of my attention to writing.
I have said repeatedly that NIH is one of the true “wonders of the world.” For over six years, I have had the unparalleled privilege of leading one of the great institutions in history. Whenever an individual participates in a clinical trial or prevention effort, visits the doctor, stays in the hospital, has a medical test, or undergoes a procedure or treatment, they are benefiting from the extraordinary contribution you make to NIH’s single, great mission: improving the public’s health.
NIH has also been in the spotlight during a revolution in the biomedical sciences, one that continues to have broad and profound implications for academic institutions, industry, nonprofits, professional and scientific organizations, the health care profession, Government, and most important, for the health of the world. I am extremely fortunate to have led NIH during these unique times, which have brought with them complex challenges and amazing opportunities.
Your work will continue to transform the future of the agency and to play a key role in that revolution. Every day, people benefit from new treatments and potential cures for disabling and fatal conditions that result from your commitment and tireless dedication, even in the presence of complex problems and unprecedented challenges.
As recipients of NIH funding, you are among the world’s best, brightest, and most innovative scientists in a most competitive and challenging era for all of us. It is because of you and your contributions to science and health that NIH is known as the “crown jewel” agency of the federal government and you have every right to claim a stake in the agency’s success.
I also want to take this occasion to express my deep personal appreciation to the countless grantees who selflessly serve the NIH as volunteers on study sections, advisory councils and the many other activities the agency often calls upon you to join.
I know that my sentiments are shared by my colleagues at the NIH, and our gratitude runs deep. We are grateful for your support and the contributions you make every day.
Please feel free to distribute this message to your colleagues.
Sincerely,
Elias A. Zerhouni, M.D.